Allen Jacques

Three costs get named: shelf life consumed before a product reaches the customer, quality defects discovered downstream after months of work-in-progress and bulk inventory sit waiting on testing, release, and review, and delayed new-product introductions when stock of old versions, including old regulatory artwork, makes a fast launch too expensive. The proposed countermeasure is multi-echelon inventory optimization, which Allen Jacques describes as a way to lean out inventory without hurting service levels.

Picking up a daughter’s epi-pen at the pharmacy and finding six months of shelf life left on a product that likely started with roughly two years, because buffers and lead times had eaten about 18 months before it arrived; a copay of $150 for a product that had never been needed but always had to be on hand.

• A second example: an operator spotted a vial defect on a contract manufacturer’s packaging line.
• It surfaced three months after filling, following QC testing, batch record review, QA release, and time in bulk buffer inventory.
• The defect did not affect sterile integrity, but it prompted the quality organization to reduce lead times and lean out bulk drug product buffers.

Read original

The reasoning treats structural connectivity as a precondition for analytics, not something analytics can substitute for.

• The post points to a longer piece on the subject.
• This is a recurring stance: the inventory post's argument about buffer costs hidden across echelons points in the same direction.
• The losses come from structural disconnection, not weak prediction.

The line itself, offered as a deliberate counter to supply-chain AI hype after years working inside pharma supply chain: AI does not fix structure.

Read original

The fix, they say, is not a better forecasting model but giving supply chain a real seat at the strategic planning table from day one, bridging what is commercially assumed and what is operationally possible.

• The argument rests on the shape of biopharma: long construction and validation timelines, multi-jurisdiction regulatory approval, clinical pipelines where fewer than 10% of molecules reach market, and demand that is nearly impossible to forecast until Phase III results arrive.
• Capacity also shifts through growth, stabilization, and decline after loss of exclusivity, and through process-development yield and OEE gains that create capacity nobody planned for.
• A plan that ignores those dynamics, they write, is not built on much, and the gap compounds quietly over years.

The roughly 18-month window before launch when Phase III results finally make first-five-year demand forecastable, set against a pipeline where fewer than 10% of molecules make it to market while commercial capacity keeps moving.

Read original

One announces team sponsorship of LogiPharma Digital Connect 2026, describing curated one-to-one meetings and peer discussions with 100 senior European life sciences supply chain and digital leaders.

• Topics include AI, automation, planning, and digital transformation.
• The other is a short congratulations post noting that nine OMP customers appear in the Gartner Supply Chain Top 25 and naming two individuals at AstraZeneca and J&J.
• Together, they suggest a preference for executive, curated life-sciences settings over broad-reach content, and an interest in planning-platform adoption and analyst recognition.
• The posts indicate priorities and audience, not ideas Jacques has developed.

A sponsorship post invites attendees to connect and links to an invitation request for an event limited to 100 senior leaders; a hashtagged recognition post offers no operational detail.

Read original · Original 2

The post shows what can go wrong when buffers and long lead times become structural, and what costs a supply-chain team should examine.

Jacques makes inventory costs tangible with a personal example: an epi-pen reached a pharmacy with only six months of shelf life remaining, after buffers and lead times had consumed 18 months.

• They then describe a vial defect detected during packaging after a three-month delay for testing, record review, release, and inventory buffering.
• The defect did not compromise sterility, but the episode prompted a lead-time reduction effort and smaller bulk-drug-product buffers.
• The post also connects excess inventory to delayed product launches and obsolete packaging when regulatory artwork changes.
• Its central point: inventory reduction involves product shelf life, quality visibility, and launch flexibility—not just cash flow—and optimization must preserve service levels.

For brands planning a campaign

Use this as the starting point for a webinar on multi-echelon inventory optimization.

• Build the discussion around balancing buffers against shelf life, quality feedback, and launch agility.
• Ask where end-to-end visibility and optimization can reduce inventory without weakening service or safety.

It explains why a long-term plan can fail even when its forecasts look precise: assumptions must keep pace with clinical, commercial, and manufacturing changes.

Jacques argues that long-range biopharma capacity plans must account for manufacturing realities.

• They point to long construction and validation timelines, regulatory approvals across jurisdictions, uncertain clinical pipelines—with fewer than 10% of molecules reaching market—and demand that remains hard to forecast until roughly 18 months before launch.
• They also note that products change through growth, stabilization, and decline, while process-development gains can create unplanned capacity.
• Their proposed response is to involve supply chain in strategic planning from the start, not only as a late reviewer.

For brands planning a campaign

Use this as a contrast to the inventory post: optimization is not only about local buffers, but also about connecting near-term operating choices to uncertain long-term capacity plans. A speaker or case study could explore how multi-echelon decisions respond to changing demand and capacity assumptions.

The post shows that Jacques's public posts include event promotion, while making clear that this post alone does not demonstrate Jacques's approach to teaching or inventory optimization.

This event announcement describes a planned gathering of 100 senior European life-sciences supply-chain and digital leaders, with curated one-to-one meetings and peer discussions.

• It names AI, automation, planning, and digital transformation as discussion areas.
• Unlike the two operational posts, it is promotional copy rather than a worked example or argument.

For brands planning a campaign

The post supports considering a peer-discussion format for a campaign, but it does not establish the event’s results or Jacques’s role beyond the stated sponsorship. A webinar brief should be grounded in the more detailed inventory post and confirm any proposed event or partnership arrangements separately.

The first is shelf life: Jacques describes picking up their daughter's epi-pen with six months of usable life left on a product that started with roughly two years, because buffers and lead times across the chain had consumed the rest.

• They note that safety stock of work-in-progress and finished goods directly cuts the shelf life customers receive.
• The second is quality defects found downstream: at a hemophilia product, an operator at a contract manufacturer spotted a vial defect, but a three-month gap between filling and packaging—caused by QC testing, batch record review, QA release, and bulk buffer inventory—meant the issue surfaced far from where it originated.
• The third is delayed new-product introductions, where excess inventory of old versions, including old artwork, makes fast launches expensive and creates obsolescence.
• Jacques points to multi-echelon inventory optimization as the capability that leans out inventory without hurting service levels.

Builds the case as a numbered list grounded in named first-person operational anecdotes, then names the technique—multi-echelon inventory optimization—rather than stopping at diagnosis.

Jacques argues that inventory does not equate to cash flow in the way payables and receivables do, because a significant part of cost of goods sold is depreciation of facilities and equipment. They defer the point rather than develop it in the post.

For brands planning a campaign

This post offers a concrete opening for a webinar on multi-echelon inventory optimization: Jacques describes an epi-pen with six months of usable life left, gives a worked example of a defect caught late, and names the technique the software supports.

Examples: Source 1

The position treats structural connectivity as a precondition for analytics, not a substitute for it, and closes by pointing readers to a longer piece Jacques wrote on the subject.

For brands planning a campaign

Jacques makes a blunt, slightly counter-hype claim in public, giving a software vendor a natural debate hook: Is end-to-end data structure a prerequisite for AI in planning, and where does inventory optimization fit in that sequence?

Examples: Source 1

They lay out why the problem is hard: construction and validation take years, regulatory approval spans jurisdictions, innovative pipelines run through three or four clinical stages, and fewer than 10% of molecules reach market.

• Even for those that do, first-five-year demand is nearly impossible to forecast until Phase III results arrive, roughly 18 months before launch.
• Commercial capacity then shifts through growth, stabilization, and decline after loss of exclusivity, while process development yield and OEE gains create capacity nobody planned for.
• Jacques concludes that the fix is not a better forecasting model, but giving supply chain a genuine seat at the strategic table as a builder from day one, bridging what is commercially assumed and what is operationally possible.

Uses pipeline attrition rates and stage timing—Phase III, 18 months to launch, and loss of exclusivity—to show why forecast accuracy alone cannot solve the planning problem, then closes with an organizational recommendation.

For brands planning a campaign

A webinar pairing long-range capacity planning with inventory optimization can use Jacques's framing as its premise, then show where software helps.

• Their line, "not a better forecasting model," gives the session a question to answer.
• Their emphasis on supply chain as a builder rather than a validator also points to an executive-level audience.

Examples: Source 1

They list AI, automation, planning, and digital transformation as conversation topics, invite attendees to connect, and link to an invitation request.

Short first-person-plural announcement built around a named event, a specific audience size and seniority, and a direct contact invitation.

The post is organizational sponsorship text, not a personal endorsement or statement of payment. Ask which organization is behind "we"; the post does not identify it.

For brands planning a campaign

Jacques creates sponsor-facing content for an executive life-sciences audience and works in curated, invitation-style formats, making a thought-leadership webinar or senior roundtable a better fit than a broad-reach content campaign.

Examples: Source 1

It offers recognition rather than analysis, with no argument, method, or operational detail.

The post names OMP customers and individuals Arun Krishnan and Joe Bitterman, and notes AstraZeneca's and J&J's recognition; it does not describe Jacques's own role or employer.

For brands planning a campaign

Jacques follows planning-platform adoption and analyst rankings, so vendor customer-proof content is likely to earn an organic share from Jacques, but this gives little indication of a topic preference because the post carries no analysis to build a session on.

Examples: Source 1

Pfizer is the only employer named. Ask for the dates and role title to assess the employment's recency and duration.

Original disclosure

While at Pfizer I attended a monthly cashflow meeting where the CFO grilled procurement about increasing payables, regional finance about reducing receivables, and me about reducing inventory.

View example

The sponsoring organization is not named; ask which company is behind the sponsorship.

Original disclosure

We're proud to be sponsoring LogiPharma Digital Connect 2026!

View example

The post reads as though they are within OMP's orbit but does not state their employer, client, or other connection to the supply chain planning vendor.

• The AstraZeneca and Johnson & Johnson references are congratulations, not disclosed commercial ties.
• Ask what their connection to OMP is.

View example

Like Jacques, they draw on day-to-day planning work rather than vendor or analyst framing.

The setting is utility operations and materials management — cable, meters, PPE and critical spares — not biopharma. The focus is separating demand planning from supply planning and keeping min-max levels current, rather than multi-echelon optimization or clinical-stage capacity.

Read original · Original 2

Lewis aggregates sector news, licensing deals and M&A activity, and frames what changes when disciplines are aligned.

• Jacques draws on personal operating experience to argue for a specific planning method.
• Lewis’s posts offer no inventory or planning methodology.

Read original · Original 2

The subject is packaging sustainability and extended producer responsibility compliance, with a strong webinar and event promotion component, rather than pharmaceutical manufacturing and inventory planning.

Read original · Original 2

Two posts make the case directly.

• The first (15 July 2026) separates what demand planning owns from what supply planning owns, then lists the consequences of blurring them into one role: shortages and stockouts, expediting and firefighting, lower forecast accuracy, excess and obsolete inventory, weaker service levels, higher operating costs and more cash tied up.
• The second (1 September 2026) explains min-max planning as a balance between stockouts and tied-up capital, and identifies the inputs that should drive the levels: average usage, storm and emergency demand variability, supplier lead times, safety stock needs, storage and yard constraints, and construction or customer service requirements.
• For a sponsor selling planning and inventory software to utilities, this is closer to buyers’ daily work than pharma shelf-life examples.

The context is utility operations: cable, meters, PPE, critical spare parts and storm response.

• The examples do not address pharma-specific concerns such as shelf life for emergency-use medicines, quality release, clinical pipelines or long-range capacity planning.
• Pharma audiences can follow the demand-versus-supply-planning framework, but the examples do not map to regulated manufacturing, and min-max is a replenishment method, not multi-echelon inventory optimization.
• To keep a pharma audience, ask for a pharma co-speaker or a rebuilt set of examples.

Examples: Source 1 · Source 2

One post (18 May 2026) is a news digest covering Bristol Myers Squibb's licensing deal with Jiangsu Hengrui, FDA leadership departures, Takeda's 4,500 job cuts, Mounjaro overtaking Keytruda, Daiichi Sankyo's oncology revenue target, an INTERPOL seizure of six million illicit medicines, the EU's provisional Critical Medicines Act deal, Moderna's mRNA hantavirus research, Isomorphic Labs' $2.1B raise and other deal and funding items. The second (4 September 2026) announces Project Farma's completed acquisition of SimoTech and argues that engineering, quality, automation, digital systems and operations must be aligned across the facility lifecycle rather than optimized one discipline at a time.

Neither post teaches inventory policy, safety stock, lead-time or buffer design, so neither covers the proposed webinar’s core.

• The digest format also dates quickly: its value is being current, not durable.
• The acquisition post is an organisation announcement, not buyer-facing analysis.
• With Dan Lewis, the session becomes an industry scan or a facility-lifecycle and automation conversation; another speaker would need to cover multi-echelon inventory optimization.

Examples: Source 1 · Source 2

One post (27 August 2026), promoting a LinkedIn Live session, captures the question packaging leaders keep asking after the first compliance wave: registered, reported, fees paid, now what?

• It argues that meeting the reporting deadline is not the same as building a system for escalating requirements and multi-state complexity.
• Teams making headway connect packaging data to finance, procurement, legal and engineering rather than adding tools or spreadsheet headcount.
• The second (24 August 2026) examines Oregon's Recycling Modernization Act, noting producer funding for more than 36,000 recycling carts, 11 collection trucks, 34 RecycleOn Centers and $30 million in sorting-facility upgrades.
• It then asks how packaging design trade-offs shift as collection and sorting change: lightweighting that risks compression strength, barrier performance or damage rates, and material changes that work only if the package can be collected, sorted and processed at scale.

This is a packaging compliance and enterprise-data topic for packaging, sustainability, finance and legal stakeholders, not an inventory optimization topic for supply chain and planning leaders.

• A pharma supply chain software sponsor would be selling to a different function with a different budget owner.
• The cross-functional governance argument and engineering trade-offs can strengthen a session about connected planning data, but the buyer decision is different from the one addressed by an inventory optimization session for supply chain and planning leaders.

Examples: Source 1 · Source 2